Neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?
作者信息
Deboever Nathaniel, Zhang Jianjun
机构信息
Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Transl Lung Cancer Res. 2022 Dec;11(12):2360-2363. doi: 10.21037/tlcr-22-828.
Abstract
摘要
相似文献
1
Neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?肺癌的新辅助化疗免疫疗法：多少算过度？
Transl Lung Cancer Res. 2022 Dec;11(12):2360-2363. doi: 10.21037/tlcr-22-828.
2
Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study.新辅助化疗免疫疗法在非小细胞肺癌中的疗效：一项真实世界、多中心、回顾性研究
Transl Lung Cancer Res. 2024 Apr 29;13(4):849-860. doi: 10.21037/tlcr-24-17. Epub 2024 Apr 18.
3
Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.新辅助化疗免疫治疗改变非小细胞肺癌（NSCLC）患者的 CD4(+)CD25(+)调节性 T 细胞（Treg）。
Lung Cancer. 2014 Jul;85(1):81-7. doi: 10.1016/j.lungcan.2014.04.001. Epub 2014 Apr 13.
4
Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer.新辅助化疗或化疗免疫治疗后，切除的非小细胞肺癌的不同病理反应和组织学特征。
Front Oncol. 2023 Feb 9;13:1115156. doi: 10.3389/fonc.2023.1115156. eCollection 2023.
5
Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.新辅助化疗免疫治疗的病理完全缓解与非小细胞肺癌纵隔淋巴结（N2 淋巴结）的外周血免疫细胞亚群和转移状态相关。
Lung Cancer. 2022 Oct;172:43-52. doi: 10.1016/j.lungcan.2022.08.002. Epub 2022 Aug 10.
6
Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer.非小细胞肺癌新辅助免疫治疗疗效预测与监测的进展
Front Oncol. 2023 May 17;13:1145128. doi: 10.3389/fonc.2023.1145128. eCollection 2023.
7
Multiparametric MRI for evaluation of pathological response to the neoadjuvant chemo-immunotherapy in resectable non-small-cell lung cancer.多参数 MRI 评估可切除性非小细胞肺癌新辅助化疗免疫治疗的病理反应。
Eur Radiol. 2023 Dec;33(12):9182-9193. doi: 10.1007/s00330-023-09813-8. Epub 2023 Jun 29.
8
Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature.局部晚期非小细胞肺癌的新辅助化疗免疫治疗：文献综述
J Clin Med. 2022 May 7;11(9):2629. doi: 10.3390/jcm11092629.
9
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.新辅助免疫检查点抑制剂在可切除非小细胞肺癌中的应用：一项系统评价。
ESMO Open. 2021 Oct;6(5):100244. doi: 10.1016/j.esmoop.2021.100244. Epub 2021 Aug 31.
10
Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy.新辅助化疗免疫治疗或新辅助化疗后 I-III 期非小细胞肺癌的真实世界疗效和预后因素分析。
Ann Thorac Cardiovasc Surg. 2022 Apr 20;28(2):111-120. doi: 10.5761/atcs.oa.21-00143. Epub 2021 Nov 15.
引用本文的文献
1
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions.晚期鳞状细胞肺癌的免疫治疗：现状与突出问题
Nat Rev Clin Oncol. 2025 Mar;22(3):200-214. doi: 10.1038/s41571-024-00979-8. Epub 2025 Jan 6.
2
The opportunities and challenges of perioperative therapy of localized non-small cell lung cancer-thoughts from the KEYNOTE-671 trial.局限性非小细胞肺癌围手术期治疗的机遇与挑战——来自KEYNOTE-671试验的思考
Transl Lung Cancer Res. 2023 Nov 30;12(11):2347-2352. doi: 10.21037/tlcr-23-570. Epub 2023 Nov 14.
3
Erratum to neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?肺癌新辅助化疗免疫治疗勘误：多少才算过量？
Transl Lung Cancer Res. 2023 Feb 28;12(2):393-394. doi: 10.21037/tlcr-2023-2. Epub 2023 Feb 20.
本文引用的文献
1
Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers.局部晚期非小细胞肺癌的术前免疫化疗：临床结局、最佳周期数及外周免疫标志物分析
Transl Lung Cancer Res. 2022 Dec;11(12):2364-2381. doi: 10.21037/tlcr-22-439.
2
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
3
Current Surgical Indications for Non-Small-Cell Lung Cancer.非小细胞肺癌的当前手术指征
Cancers (Basel). 2022 Feb 28;14(5):1263. doi: 10.3390/cancers14051263.
4
Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.外科视角下的非小细胞肺癌新辅助免疫治疗。
Ann Thorac Surg. 2022 Oct;114(4):1505-1515. doi: 10.1016/j.athoracsur.2021.06.069. Epub 2021 Jul 30.
5
What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer.什么是新辅助治疗？可切除非小细胞肺癌新辅助化疗免疫治疗
J Clin Oncol. 2021 Sep 10;39(26):2855-2858. doi: 10.1200/JCO.21.01446. Epub 2021 Aug 2.
6
Lung cancer.肺癌。
Lancet. 2021 Aug 7;398(10299):535-554. doi: 10.1016/S0140-6736(21)00312-3. Epub 2021 Jul 21.
7
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.SAKK 16/14：在 IIIA（N2）期非小细胞肺癌患者中，新辅助化疗联合度伐利尤单抗：一项多中心单臂 II 期试验。
J Clin Oncol. 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. Epub 2021 Jul 12.
8
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.可切除非小细胞肺癌的新辅助纳武利尤单抗或纳武利尤单抗联合伊匹单抗：Ⅱ期随机 NEOSTAR 试验。
Nat Med. 2021 Mar;27(3):504-514. doi: 10.1038/s41591-020-01224-2. Epub 2021 Feb 18.
9
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.PACIFIC 试验的更新：放化疗后 durvalumab 治疗 III 期非小细胞肺癌的 4 年生存结果
J Thorac Oncol. 2021 May;16(5):860-867. doi: 10.1016/j.jtho.2020.12.015. Epub 2021 Jan 19.
10
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.可切除非小细胞肺癌新辅助化疗联合纳武利尤单抗（NADIM）：一项开放标签、多中心、单臂、Ⅱ期临床试验。
Lancet Oncol. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. Epub 2020 Sep 24.
Zotero 插件